A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of DA-8031 After Oral Administration in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs DA 8031 (Primary)
- Indications Premature ejaculation
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 09 Mar 2013 Pharmacokinetic results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 01 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.